Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 6, 2012, Pages 601-618

  Ito, K ^a   Hutmacher, M M ^b   Corrigan, B W ^a  

^a PFIZER INC   (United States)

^b ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

ADNI; Alzheimer's disease; Bounded outcome data; Disease progression

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

AGE; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE NEUROIMAGING INITIATIVE DATABASE; APOLIPOPROTEIN E4 GENE; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT QUESTIONNAIRE; FUNCTIONAL STATUS; GENDER; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; QUESTIONNAIRE;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; DATABASES, FACTUAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES;

EID: 84880761663     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9271-3     Document Type: Article

References (27)

1. Mould DR (2006) Developing models of disease progression. In: Ette EI, Williams PJ (eds) Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons, Inc, Hoboken. doi: 10.1002/9780470087978.ch21
2. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89:11466-11470
3. Holford NH, Peace KE (1992) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89:11471-11475
4. Holford NH, Peace KE (1994) The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 47:17-23 (Pubitemid 24281306)
5. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, Alzheimer's Disease Working Group (2010) A disease progression meta-analysis model in Alzheimer's disease. Alzheimer's Dementia 6(1):39-53
6. Ito K, Corrigan B, Zhao Q, French J, Miller R et al (2011) Disease progression model for cognitive deterioration from ADNI database. Alzheimer's Dementia 7(2):151-160
7. William-Faltaos D, Chen Y, Wang, Y, Gobburu J, Zhu H (2011) Quantification of disease progression and drop-out for Alzheimer's Disease. Division of Pharmacometrics, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USA
8. Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, DiBernardo A, Narayan V, Alzheimer's Disease Neuroimaging initiative (2012) An Improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 52:629-644
9. Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K et al (2012) Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn. doi: 10.1007/s10928-012-9263-3
10. Jacob Brogren (2011) Separate vs simultaneous analysis of co-primary endpoints in Alzheimer's disease clinical trials. In: Annual meeting of the population approach group in Europe (PAGE). ISSN 1871-6032 PAGE 21, Abstr 2038, www.page-meeting.org/?abstract=2038
11. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. J Gerontol 37(3):323-329 (Pubitemid 12117513)
12. Post TM, Freijer JI, DeJongh J, Danhof M (2005) Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 22(7):1038-1049 (Pubitemid 41127061)
13. Association Alzheimer's (2011) Alzheimer's disease facts and figures. Alzheimer's Dementia 7(2):208-244
14. O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W et al (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 67(6):746-749
15. Ashford JW, Schmitt FA (2001) Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep 3:20-28
16. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532-540
17. Hutmacher MM, French JL, Krishnaswami S, Menon S (2011) Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med 30(9):935-949
18. Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401-421
19. Berk KN, Lachenbruch PA (2002) Repeated measures with zeros. Stat Methods Med Res 11:303-316
20. Beal SL, Sheiner LB, Boeckmann AJ (eds) (1989-2006) NONMEM users guides. ICON Development Solutions, Ellicott City
21. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Pharmacodyn 20:511-528 (Pubitemid 23034413)
22. Maitre PO, Bührer M, Thomson D, Stanski DR (1991) A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Pharmacodyn 19:377-384
23. Ette EI, Ludden TM (1995) Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 12:1845-1855 (Pubitemid 26031769)
24. Naj AC, Jun G, Beecham GW, Wang LS,Vardarajan BN et al (2011) Common variants of MS4A4/MS4A6E, CD2AP, CD33 and EPHA 1 are associated with late-onset Alzheimer's Disease. Nature Genetics (published online, April 3) doi: 10.1038/ng.801
25. Balsis S, Unger AA, Benge JF, Geraci L, Doody RS (2012) Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimer's Dementia 8(4):288-294
26. Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC (2012). Application of item response theory to ADAS-cog scores modelling in Alzheimer's disease. In: Annual meeting of the population approach group in Europe (PAGE), ISSN 1871-6032 PAGE 21, Abstr 2318 [ www.page-meeting.org/?abstract=2318 ]
27. De Meyer G, Shapiro F, Vanderstichele H et al (2010) Diagnosis independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67:949-956